TAS6417

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

12 competitors in Advanced or Metastatic NSCLC

#DrugCompanyPhaseTrials

1

Opdivo

Bristol-Myers Squibb

Phase 3

22

Trodelvy

Gilead

Phase 2

13

Paraplatin

AAvyxa

Phase 2

24

Imfinzi

AstraZeneca

Phase 1

25

DATROWAY

Daiichi Sankyo

Phase 1

16

TAS6417

Taiho Oncology, Inc.

Phase 3

17

HS-10504

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

18

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 2

19

MEDI5752

AstraZeneca

Phase 1

110

AZD2936

AstraZeneca

Phase 1

1Show 3 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Advanced or Metastatic NSCLC1 trial

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Recruiting·Taiho Oncology, Inc.·Phase 2·NCT05967689·220 enrolled

Exon 201 trial

Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Active, not recruiting·Taiho Oncology, Inc.·Phase 3·NCT05973773·285 enrolled

NSCLC, Stage IB-IIIA1 trial

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Active, not recruiting·Taiho Oncology, Inc.·Phase 3·NCT07128199·360 enrolled

Details

Drug Info

Related News